ClinicalTrials.gg
CompletedNCT03296813TRANSFORM-HFUpdated Oct 16, 2025Results posted

TRANSFORM-HF: ToRsemide compArisoN With furoSemide FORManagement of Heart Failure

A Phase 3 interventional study of Torsemide and Furosemide in Heart Failure, sponsored by Duke University. Completed at 60 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-16.

Sponsored by Duke University · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
2,973
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies testing furosemide in Heart Failure — 5 open to participants now, 5 under way, 1 of them phase 3. Furosemide · Heart Failure.

Enrollment
Largest of 35
2,973 · median 42
Started
2018
the only one that year
Phase 3
6 of 36
1 open now
Registered
22nd of 36
by date
Lead sponsor
1 of 36
Duke University

Among the 36 studies testing furosemide in Heart Failure, this one has the largest enrollment of the 35 interventional ones that give a count, is the only one that started in 2018, is one of 6 in phase 3, and was the 22nd registered.

Heart Failure

6,332 studies on the registry are indexed under Heart Failure; 1,394 are open to participants now.

Browse Heart Failure studies →

Open to participants now

5 of the 36 studies testing furosemide in Heart Failure are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About furosemide

Furosemide: first FDA approval 1966 (LASIX), first EMA approval 2026. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 967 Heart Failure studies recruiting now, 690 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing furosemide in Heart Failure, or all of them as a file.
02

Study summary

TRANSFORM-HF is a large-scale, pragmatic, randomized, unblinded clinical effectiveness study comparing torsemide versus furosemide as treatment for heart failure. Approximately 6,000 patients with heart failure will be enrolled. The primary objective of the TRANSFORM-HF study is to compare the treatment strategy of torsemide versus furosemide on clinical outcomes over 12 months in patients with heart failure who are hospitalized.

Read the detailed description
  • This study will be a randomized, unblinded, two-arm, multi-center clinical trial of patients with heart failure who are hospitalized. Heart failure need not be the reason for hospitalization. Patients will be randomized 1:1 to either oral torsemide OR oral furosemide prior to hospital discharge. Oral dosing of torsemide compared to furosemide will be 1mg:2mg. The specific loop diuretic dose will be at the discretion of the treating physician with the above noted conversion.
  • Trial enrollment occurs before hospital discharge, at the discretion of the healthcare provider.
  • As appropriate, adherence to the randomized medication will be encouraged during the remainder of hospitalization and will continue post-discharge. Patients will receive follow-up per standard care without any additional study-specific visits.
  • Patients will have 30-day, 6-month and 12-month follow-up phone contacts for assessments of vital status, interval hospitalizations, adherence, and quality of life. "Central follow-up" and collection of hospital discharge summaries via IRB-approved mechanisms. Subsets of patients enrolled early in the study have additional phone contacts beyond 12 months, up to 30 months, at six month intervals, to document vital status.
03

Conditions studied

  • Heart Failure

Browse trials for

Keywords

  • loop diuretic
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient hospitalized (≥ 24 hours or over a change in calendar date) with worsening of chronic heart failure, or new diagnosis of heart failure AND meets one of the following criteria:

    1. Has a (EF) ≤40% within 24 months prior to and including index hospitalization by any method (with most recent value used to determine eligibility)
    2. Has an elevated natriuretic peptide level (either NT-pro-B-type natriuretic peptide or B-type natriuretic peptide) during index hospitalization as measured by local laboratory (with most recent value used to determine eligibility)
  2. Plan for a daily outpatient oral loop diuretic regimen upon hospital discharge with anticipated need for long-term loop diuretic use
  3. ≥ 18 years of age
  4. Signed

Exclusion criteria

Exclusion Criteria:

  1. End-stage renal disease requiring renal replacement therapy
  2. Inability or unwillingness to comply with the study requirements
  3. History of heart transplant or actively listed for heart transplant
  4. Implanted left ventricular assist device or implant anticipated \<3 months
  5. Pregnant or nursing women
  6. or other non-cardiac condition limiting to \<12 months
  7. Known to furosemide, torsemide, or related agents
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
2,973 participants (actual)

Study arms

  • Active comparator
    Torsemide

    Oral dosing of torsemide compared to furosemide will be 1mg:2-4mg.

    Drug: Torsemide

  • Active comparator
    Furosemide

    Oral dosing of torsemide compared to furosemide will be 1mg:2-4mg. For patients receiving loop diuretics other than furosemide, conversion to furosemide equivalents will be as follows: 1 mg oral torsemide = 2-4 mg oral furosemide 1 mg oral or intravenous bumetanide = 40 mg oral furosemide

    Drug: Furosemide

Interventions

06

What researchers measure

Primary outcomes

  1. All-cause Mortality, as Measured by Follow-up Phone Call or NDI

    Death information was obtained from the Call Center through 30 months for patients 1-500, through 24 months for patients 501-1000, through 18 months for patients 1001-1500, and through 12 months for the remaining patients (except those who were randomized \< 12 months when the study was stopped by the DSMB). Also death information was obtained through searches of the 2018-2021 National Death Index (NDI) database.

    Time frame: up to 30 months

Secondary outcomes

  1. All-cause Mortality or All-cause Hospitalization, as Measured by Follow-up Phone Call or NDI (for Death)

    The time-to-event analysis of all-cause mortality or all-cause primary re-hospitalization was based on the time from randomization through death or the first primary re-hospitalization through 12 months. Patients who died or whose first all-cause re-hospitalization was after month 12 were censored at month 12. Patients who did not have a re-hospitalization and were alive were censored at the minimum of the time of the last re-hospitalization assessment or month 12.

    Time frame: up to 12 months

  2. Total Re-hospitalizations, as Measured by Follow-up Phone Call

    Total all-cause primary re-hospitalization was defined as a hospitalization after the index hospitalization through month 12 that met one of the following criteria: 1.) at least a 24-hour stay (or a change in calendar date if the time of admission/discharge is not available) or 2.) reported as an in-patient admission by the patient/proxy with an admission date (complete or month and year) and no discharge date (i.e., length of stay could not be derived). Unit of measurement is the total number of re-hospitalizations for each subject (e.g., if a subject had 3 re-hospitalizations, then the outcome is 3 for the subject).

    Time frame: up to 12 months

  3. All-cause Mortality or All-cause Hospitalization, as Measured by Follow-up Phone Call or NDI (for Death)

    All-cause mortality or all-cause hospitalization over 30 days

    Time frame: 30 days

  4. Change in Health-related Quality of Life (QOL), as Measured by Follow-up Phone Call

    QOL as assessed by the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS) (range, 0-100 with 100 indicating best health status). The KCCQ was administered prior to randomization (collected by the site) and at Months 1, 6 and 12 (ascertained at the Call Center visits). The outcome is the least square means in Torsemide and Furosemide groups where the difference = Torsemide mean minus Furosemide mean at the monthly assessment.

    Time frame: Baseline, 1 month, 6 months, 12 months

  5. Symptoms of Depression as Measured by the Patient Health Questionnaire-2 (PHQ-2)

    Depression was assessed by the Patient Health Questionnaire-2 (PHQ-2) over 12 months. The PHQ-2 inquires about the frequency of depressed mood and anhedonia (inability to feel pleasure) over the past two weeks. The responses to the questions are scored 0 = Not at all, 1 = Several days, 2 = More than half the days, and 3 = Nearly every day. The PHQ-2 total score is obtained by adding the score for each question. The PHQ-2 total score ranges from 0-6. Reported as the number of patients with a total score \<3 versus \>=3.

    Time frame: Month 1, month 6, month 12

07

Results

Posted Oct 16, 2025

Participant flow

Participant flow — Overall Study
MilestoneTorsemideFurosemide
Started14311428
Completed13781368
Not completed5360

Outcome measures

PrimaryAll-cause Mortality, as Measured by Follow-up Phone Call or NDI

Death information was obtained from the Call Center through 30 months for patients 1-500, through 24 months for patients 501-1000, through 18 months for patients 1001-1500, and through 12 months for the remaining patients (except those who were randomized \< 12 months when the study was stopped by the DSMB). Also death information was obtained through searches of the 2018-2021 National Death Index (NDI) database.

Time frame:
up to 30 months
Reported as:
Count of participants · Participants
All-cause Mortality, as Measured by Follow-up Phone Call or NDI
ParticipantsTorsemideFurosemide
All-cause Mortality, as Measured by Follow-up Phone Call or NDI373374
Statistical analysis
  • Torsemide vs Furosemide · Regression, Cox · p = 0.765 (P-value not adjusted for multiple comparisons.) · Hazard ratio (hr): 1.022 · 95% CI 0.885 to 1.180
SecondaryAll-cause Mortality or All-cause Hospitalization, as Measured by Follow-up Phone Call or NDI (for Death)

The time-to-event analysis of all-cause mortality or all-cause primary re-hospitalization was based on the time from randomization through death or the first primary re-hospitalization through 12 months. Patients who died or whose first all-cause re-hospitalization was after month 12 were censored at month 12. Patients who did not have a re-hospitalization and were alive were censored at the minimum of the time of the last re-hospitalization assessment or month 12.

Time frame:
up to 12 months
Reported as:
Count of participants · Participants
All-cause Mortality or All-cause Hospitalization, as Measured by Follow-up Phone Call or NDI (for Death)
ParticipantsTorsemideFurosemide
All-cause Mortality or All-cause Hospitalization, as Measured by Follow-up Phone Call or NDI (for Death)677704
Statistical analysis
  • Torsemide vs Furosemide · Regression, Cox · p = 0.113 (For secondary analyses, a statistically significant p-value \< 0.005 was pre-specified to address the multiple planned analyses and help control the overall type I error rate.) · Hazard ratio (hr): 0.918 · 95% CI 0.826 to 1.020
SecondaryTotal Re-hospitalizations, as Measured by Follow-up Phone Call

Total all-cause primary re-hospitalization was defined as a hospitalization after the index hospitalization through month 12 that met one of the following criteria: 1.) at least a 24-hour stay (or a change in calendar date if the time of admission/discharge is not available) or 2.) reported as an in-patient admission by the patient/proxy with an admission date (complete or month and year) and no discharge date (i.e., length of stay could not be derived). Unit of measurement is the total number of re-hospitalizations for each subject (e.g., if a subject had 3 re-hospitalizations, then the outcome is 3 for the subject).

Time frame:
up to 12 months
Reported as:
Number · re-hospitalizations
Total Re-hospitalizations, as Measured by Follow-up Phone Call
re-hospitalizationsTorsemideFurosemide
Total Re-hospitalizations, as Measured by Follow-up Phone Call940987
Statistical analysis
  • Torsemide vs Furosemide · Regression, Linear · p = 0.366 (For secondary analyses, a statistically significant p-value \< 0.005 was pre-specified to address the multiple planned analyses and help control the overall type I error rate.) · Risk ratio (rr): 0.945 · 95% CI 0.836 to 1.068
SecondaryAll-cause Mortality or All-cause Hospitalization, as Measured by Follow-up Phone Call or NDI (for Death)

All-cause mortality or all-cause hospitalization over 30 days

Time frame:
30 days
Reported as:
Count of participants · Participants
All-cause Mortality or All-cause Hospitalization, as Measured by Follow-up Phone Call or NDI (for Death)
ParticipantsTorsemideFurosemide
All-cause Mortality or All-cause Hospitalization, as Measured by Follow-up Phone Call or NDI (for Death)149157
Statistical analysis
  • Torsemide vs Furosemide · Regression, Cox · p = 0.610 (For secondary analyses, a statistically significant p-value \< 0.005 was pre-specified to address the multiple planned analyses and help control the overall type I error rate.) · Hazard ratio (hr): 0.943 · 95% CI 0.753 to 1.181
SecondaryChange in Health-related Quality of Life (QOL), as Measured by Follow-up Phone Call

QOL as assessed by the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS) (range, 0-100 with 100 indicating best health status). The KCCQ was administered prior to randomization (collected by the site) and at Months 1, 6 and 12 (ascertained at the Call Center visits). The outcome is the least square means in Torsemide and Furosemide groups where the difference = Torsemide mean minus Furosemide mean at the monthly assessment.

Time frame:
Baseline, 1 month, 6 months, 12 months
Reported as:
Least squares mean · score on a scale
Change in Health-related Quality of Life (QOL), as Measured by Follow-up Phone Call
score on a scaleTorsemideFurosemide
Baseline to Month 169.52 (67.53 to 71.51)68.22 (66.22 to 70.23)
Baseline to Month 670.61 (68.53 to 72.70)71.01 (68.91 to 73.10)
Baseline to Month 1270.00 (67.85 to 72.15)69.98 (67.80 to 72.16)
Statistical analysis
  • Torsemide vs Furosemide · Mixed Models Analysis · p = 0.194 (For secondary analyses, a statistically significant p-value \< 0.005 was pre-specified to address the multiple planned analyses and help control the overall type I error rate.) · Mean difference (final values): 1.30 · 95% CI -0.66 to 3.26
  • Torsemide vs Furosemide · Mixed Models Analysis · p = 0.718 (For secondary analyses, a statistically significant p-value \< 0.005 was pre-specified to address the multiple planned analyses and help control the overall type I error rate.) · Mean difference (final values): -0.39 · 95% CI -2.53 to 1.74
  • Torsemide vs Furosemide · Mixed Models Analysis · p = 0.987 (For secondary analyses, a statistically significant p-value \< 0.005 was pre-specified to address the multiple planned analyses and help control the overall type I error rate.) · Mean difference (final values): 0.02 · 95% CI -2.26 to 2.30
SecondarySymptoms of Depression as Measured by the Patient Health Questionnaire-2 (PHQ-2)

Depression was assessed by the Patient Health Questionnaire-2 (PHQ-2) over 12 months. The PHQ-2 inquires about the frequency of depressed mood and anhedonia (inability to feel pleasure) over the past two weeks. The responses to the questions are scored 0 = Not at all, 1 = Several days, 2 = More than half the days, and 3 = Nearly every day. The PHQ-2 total score is obtained by adding the score for each question. The PHQ-2 total score ranges from 0-6. Reported as the number of patients with a total score \<3 versus \>=3.

Time frame:
Month 1, month 6, month 12
Reported as:
Count of participants · Participants
Symptoms of Depression as Measured by the Patient Health Questionnaire-2 (PHQ-2)
ParticipantsTorsemideFurosemide
Month 1 — PHQ-2 score < 3790813
Month 1 — PHQ-2 score > = 3148150
Month 6 — PHQ-2 score < 3658672
Month 6 — PHQ-2 score > = 3113119
Month 12 — PHQ-2 score < 3533537
Month 12 — PHQ-2 score > = 39582
Statistical analysis
  • Torsemide vs Furosemide · Wilcoxon (Mann-Whitney) · p = 0.904 (For secondary analyses, a statistically significant p-value \< 0.005 was pre-specified to address the multiple planned analyses and help control the overall type I error rate.)
  • Torsemide vs Furosemide · Wilcoxon (Mann-Whitney) · p = 0.829 (For secondary analyses, a statistically significant p-value \< 0.005 was pre-specified to address the multiple planned analyses and help control the overall type I error rate.)
  • Torsemide vs Furosemide · Wilcoxon (Mann-Whitney) · p = 0.342 (For secondary analyses, a statistically significant p-value \< 0.005 was pre-specified to address the multiple planned analyses and help control the overall type I error rate.)

Adverse events

Collected over All-Cause Mortality data was collected for up to 30 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Torsemide373/1,431 (26.1%)——
Furosemide374/1,428 (26.2%)——

Baseline characteristics

Age, Continuous
Age, Continuous(years)TorsemideFurosemideTotal
Mean64 ± 1465 ± 1464.5 ± 14
Sex: Female, Male
Sex: Female, Male(Participants)TorsemideFurosemideTotal
Female4985571055
Male9338711804
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)TorsemideFurosemideTotal
Hispanic or Latino7580155
Not Hispanic or Latino135513452700
Unknown or Not Reported134
Race (NIH/OMB)
Race (NIH/OMB)(Participants)TorsemideFurosemideTotal
American Indian or Alaska Native9312
Asian372663
Native Hawaiian or Other Pacific Islander13720
Black or African American474494968
White8318371668
More than one race6558123
Unknown or Not Reported235
Region of Enrollment
Region of Enrollment(Participants)TorsemideFurosemideTotal
United States143114282859
08

Study locations

60 sites
  • Russel Medical Center
    Alexander City, Alabama 35010, United States
  • The Heart Center, PC
    Huntsville, Alabama 35801, United States
  • University of Arizona
    Tucson, Arizona 85724, United States
  • V.A. Greater Los Angeles Healthcare System
    Los Angeles, California 90073, United States
  • Kaiser Permanente Medical Center
    San Francisco, California 94115, United States
  • Saint Francis Hospital and Medical Center
    Hartford, Connecticut 06105, United States
  • Yale
    New Haven, Connecticut 06511, United States
  • West Haven VA Medical Center
    West Haven, Connecticut 06516, United States
  • Holy Cross Hospital
    Fort Lauderdale, Florida 33308, United States
  • University of Florida - Gainesville
    Gainesville, Florida 32610, United States
  • Emory Health Care
    Atlanta, Georgia 30322, United States
  • Augusta University
    Augusta, Georgia 30912, United States
  • Queens Medical Center
    Honolulu, Hawaii 96813, United States
  • Fox Valley Clinical Research Center
    Aurora, Illinois 60506, United States
  • Northwestern Memorial Hospital
    Chicago, Illinois 60611, United States
  • University of Chicago
    Chicago, Illinois 60637, United States
  • Loyola University Medical Center
    Maywood, Illinois 60153, United States
  • Methodist Medical Center of Illinois
    Peoria, Illinois 61606, United States
  • Indiana University Health Bloomington Hospital
    Bloomington, Indiana 47402, United States
  • Indiana University Medical Center
    Indianapolis, Indiana 46202, United States
  • University of Iowa Hospitals and Clinics
    Iowa City, Iowa 52242, United States
  • University Medical Center
    New Orleans, Louisiana 70112, United States
  • Oschner Clinic
    New Orleans, Louisiana 70121, United States
  • VA Medical Center/University of Maryland
    Baltimore, Maryland 21201, United States
  • Shady Grove Medical Center
    Rockville, Maryland 20850, United States
  • University of Michigan Medical Center
    Ann Arbor, Michigan 48109, United States
  • Henry Ford Hospital
    Detroit, Michigan 48202, United States
  • Saint Joseph Mercy Health System / Michigan Heart
    Ypsilanti, Michigan 48197, United States
  • University of Minnesota
    Minneapolis, Minnesota 55455, United States
  • University of Mississippi Medical Center
    Jackson, Mississippi 29216, United States
  • Lester E. Cox Health Systems
    Springfield, Missouri 65807, United States
  • Washington University School of Medicine
    St Louis, Missouri 63110, United States
  • AtlantiCare Regional Medical Center
    Pomona, New Jersey 08240, United States
  • Presbyterian/Brooklyn Methodist Hospital
    Brooklyn, New York 11215, United States
  • North Shore University Hospital
    Manhasset, New York 11030, United States
  • Weill Cornell Medical College
    New York, New York 10021, United States
  • Mount Sinai
    New York, New York 10029-6574, United States
  • Columbia University Medical Center
    New York, New York 10032, United States
  • Stony Brook University Hospital
    Stony Brook, New York 11794, United States
  • Montefore Medical Center - Albert Einstein University Hospital
    The Bronx, New York 10461, United States
  • University of North Carolina School of Medicine
    Chapel Hill, North Carolina 27514, United States
  • Duke (Duke Heart Center)
    Durham, North Carolina 27710, United States
  • Novant Health Matthews Medical Center
    Matthews, North Carolina 28240, United States
  • New Hanover Regional Medical Center
    Wilmington, North Carolina 28401, United States
  • University Hospitals Case Medical Center
    Cleveland, Ohio 44106, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • Abington Memorial Hospital
    Abington, Pennsylvania 19001, United States
  • Good Samaritan Hospital
    Ephrata, Pennsylvania 17522, United States
  • Drexel University College of Medicine
    Philadelphia, Pennsylvania 19102, United States
  • Jefferson University Hospital
    Philadelphia, Pennsylvania 19107, United States
  • Main Line Health System
    Wynnewood, Pennsylvania 19096, United States
  • Greenville Hospital System University Medical Center
    Greenville, South Carolina 29605, United States
  • Black Hills Cardiovascular Research
    Rapid City, South Dakota 57701, United States
  • Baylor University Medical Center
    Dallas, Texas 75246, United States
  • Intermountain Medical Center
    Murray, Utah 84107, United States
  • University of Utah Hospitals and Clinics
    Salt Lake City, Utah 84132, United States
  • Inova Health Care Services
    Falls Church, Virginia 22042, United States
  • Sentara Norfolk General Hospital
    Norfolk, Virginia 23507, United States
  • Virginia Commonwealth University Health
    Richmond, Virginia 23298, United States
  • Froedtert Hospital
    Milwaukee, Wisconsin 53226, United States
09

References and documents

Publications

  • Tong G, Zeng Y, Greene SJ, Anstrom KJ, Testani J, Mentz RJ, Li F, Velazquez EJ. Comparative effectiveness of torsemide vs furosemide in the management of heart failure patients: win-ratio reanalysis of the TRANSFORM-HF trial. Am Heart J. 2026 Jul 8:107525. doi: 10.1016/j.ahj.2026.107525. Online ahead of print. PubMed 42419438 ↗
  • Rao VS, Cox ZL, Ivey-Miranda JB, Neville D, Balkcom N, Moreno-Villagomez J, Ramos-Mastache D, Maulion C, Bellumkonda L, Tang WHW, Collins SP, Velazquez EJ, Mentz RJ, Wilson FP, Turner JM, Wilcox CS, Ellison DH, Fang JC, Testani JM. Mechanistic Differences between Torsemide and Furosemide. J Am Soc Nephrol. 2025 Jan 1;36(1):99-107. doi: 10.1681/ASN.0000000000000481. Epub 2024 Aug 28. PubMed 39196651 ↗
  • Kittipibul V, Mentz RJ, Clare RM, Wojdyla DM, Anstrom KJ, Eisenstein EL, Ambrosy AP, Goyal P, Skopicki HA, Ketema F, Kim DY, Desvigne-Nickens P, Pitt B, Velazquez EJ, Greene SJ. On-treatment analysis of torsemide versus furosemide for patients hospitalized for heart failure: A post-hoc analysis of TRANSFORM-HF. Eur J Heart Fail. 2024 Jul;26(7):1518-1523. doi: 10.1002/ejhf.3293. Epub 2024 May 15. PubMed 38745502 ↗
  • Kapelios CJ, Greene SJ, Mentz RJ, Ikeaba U, Wojdyla D, Anstrom KJ, Eisenstein EL, Pitt B, Velazquez EJ, Fang JC; TRANSFORM-HF Investigators. Torsemide Versus Furosemide After Discharge in Patients Hospitalized With Heart Failure Across the Spectrum of Ejection Fraction: Findings From TRANSFORM-HF. Circ Heart Fail. 2024 Mar;17(3):e011246. doi: 10.1161/CIRCHEARTFAILURE.123.011246. Epub 2024 Mar 4. PubMed 38436075 ↗
  • Greene SJ, Velazquez EJ, Anstrom KJ, Clare RM, DeWald TA, Psotka MA, Ambrosy AP, Stevens GR, Rommel JJ, Alexy T, Ketema F, Kim DY, Desvigne-Nickens P, Pitt B, Eisenstein EL, Mentz RJ; TRANSFORM-HF Investigators. Effect of Torsemide Versus Furosemide on Symptoms and Quality of Life Among Patients Hospitalized for Heart Failure: The TRANSFORM-HF Randomized Clinical Trial. Circulation. 2023 Jul 11;148(2):124-134. doi: 10.1161/CIRCULATIONAHA.123.064842. Epub 2023 May 22. PubMed 37212600 ↗
  • Mentz RJ, Anstrom KJ, Eisenstein EL, Sapp S, Greene SJ, Morgan S, Testani JM, Harrington AH, Sachdev V, Ketema F, Kim DY, Desvigne-Nickens P, Pitt B, Velazquez EJ; TRANSFORM-HF Investigators. Effect of Torsemide vs Furosemide After Discharge on All-Cause Mortality in Patients Hospitalized With Heart Failure: The TRANSFORM-HF Randomized Clinical Trial. JAMA. 2023 Jan 17;329(3):214-223. doi: 10.1001/jama.2022.23924. PubMed 36648467 ↗
  • Eisenstein EL, Sapp S, Harding T, Harrington A, Velazquez EJ, Mentz RJ, Greene SJ, Sachdev V, Kim DY, Anstrom KJ. Ascertaining Death Events in a Pragmatic Clinical Trial: Insights From the TRANSFORM-HF Trial. J Card Fail. 2022 Oct;28(10):1563-1567. doi: 10.1016/j.cardfail.2022.01.020. Epub 2022 Feb 16. PubMed 35181553 ↗
  • Greene SJ, Velazquez EJ, Anstrom KJ, Eisenstein EL, Sapp S, Morgan S, Harding T, Sachdev V, Ketema F, Kim DY, Desvigne-Nickens P, Pitt B, Mentz RJ; TRANSFORM-HF Investigators. Pragmatic Design of Randomized Clinical Trials for Heart Failure: Rationale and Design of the TRANSFORM-HF Trial. JACC Heart Fail. 2021 May;9(5):325-335. doi: 10.1016/j.jchf.2021.01.013. Epub 2021 Mar 10. PubMed 33714745 ↗

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2018 to primary completion in Jul 2022, 48 months.

Results were first posted in Oct 2025, 3 years 2 months after primary completion.

Of 87 non-industry phase 3 interventional studies under Heart Failure, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's 48 months is close to that.

Counting every sponsor, half of 150 studies reached it within 39 months; a quarter within 26 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 26, 2017
First posted
Sep 28, 2017
StartActual
Jul 11, 2018
Primary completionActual
Jul 29, 2022
CompletionActual
Jul 29, 2022
Results first posted
Oct 16, 2025
Last update
Oct 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03296813
Lead sponsor
Duke University
Responsible party
Sponsor
First posted
Sep 28, 2017
Start date
Jul 11, 2018
Primary completion
Jul 29, 2022
Completion
Jul 29, 2022
Results posted
Oct 16, 2025
Last update
Oct 16, 2025

Study contacts

Eric Velazquez, MD
principal investigator · Yale University
Robert Mentz, MD
principal investigator · Duke University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Torsemide · Furosemide

Start the discussion